These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9002941)

  • 21. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.
    Castelletti D; Fracasso G; Righetti S; Tridente G; Schnell R; Engert A; Colombatti M
    Clin Exp Immunol; 2004 May; 136(2):365-72. PubMed ID: 15086403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Gribben JG; Freedman AS; Lambert JM; Kinsella J; Rabinowe SN; Eliseo L; Taylor JA; Blättler WA; Epstein CL
    Blood; 1993 May; 81(9):2263-71. PubMed ID: 8481509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys.
    Hertler AA; Schlossman DM; Borowitz MJ; Poplack DG; Frankel AE
    Cancer Immunol Immunother; 1989; 28(1):59-66. PubMed ID: 2783301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
    Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
    Grossbard ML; Lambert JM; Goldmacher VS; Spector NL; Kinsella J; Eliseo L; Coral F; Taylor JA; Blättler WA; Epstein CL
    J Clin Oncol; 1993 Apr; 11(4):726-37. PubMed ID: 7683045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
    Grossbard ML; Freedman AS; Ritz J; Coral F; Goldmacher VS; Eliseo L; Spector N; Dear K; Lambert JM; Blättler WA
    Blood; 1992 Feb; 79(3):576-85. PubMed ID: 1370636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma.
    LeMaistre CF; Rosen S; Frankel A; Kornfeld S; Saria E; Meneghetti C; Drajesk J; Fishwild D; Scannon P; Byers V
    Blood; 1991 Sep; 78(5):1173-82. PubMed ID: 1878584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.
    Schnell R; Katouzi AA; Linnartz C; Schoen G; Drillich S; Hansmann ML; Schiefer D; Barth S; Zangemeister-Wittke U; Stahel RA; Diehl V; Engert A
    Int J Cancer; 1996 May; 66(4):526-31. PubMed ID: 8635869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
    Schindler J; Gajavelli S; Ravandi F; Shen Y; Parekh S; Braunchweig I; Barta S; Ghetie V; Vitetta E; Verma A
    Br J Haematol; 2011 Aug; 154(4):471-6. PubMed ID: 21732928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V; Engert A; Schnell R; Vitetta ES
    Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma.
    Selvaggi K; Saria EA; Schwartz R; Vlock DR; Ackerman S; Wedel N; Kirkwood JM; Jones H; Ernstoff MS
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):201-7. PubMed ID: 8471594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraventricular immunotoxin therapy for leptomeningeal neoplasia.
    Laske DW; Muraszko KM; Oldfield EH; DeVroom HL; Sung C; Dedrick RL; Simon TR; Colandrea J; Copeland C; Katz D; Greenfield L; Groves ES; Houston LL; Youle RJ
    Neurosurgery; 1997 Nov; 41(5):1039-49; discussion 1049-51. PubMed ID: 9361057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice.
    Engert A; Gottstein C; Bohlen H; Winkler U; Schön G; Manske O; Schnell R; Diehl V; Thorpe P
    Int J Cancer; 1995 Oct; 63(2):304-9. PubMed ID: 7591221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.
    Grossbard ML; Fidias P; Kinsella J; O'Toole J; Lambert JM; Blattler WA; Esseltine D; Braman G; Nadler LM; Anderson KC
    Br J Haematol; 1998 Jul; 102(2):509-15. PubMed ID: 9695966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.
    Gonzalez R; Salem P; Bunn PA; Zukiwski AA; Lamb R; Benjamin RS; Spitler L; Wedel N; Robinson WA
    Mol Biother; 1991 Dec; 3(4):192-6. PubMed ID: 1768370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
    van Oosterhout YV; van Emst L; Schattenberg AV; Tax WJ; Ruiter DJ; Spits H; Nagengast FM; Masereeuw R; Evers S; de Witte T; Preijers FW
    Blood; 2000 Jun; 95(12):3693-701. PubMed ID: 10845899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo.
    Blakey DC; Skilleter DN; Price RJ; Thorpe PE
    Biochim Biophys Acta; 1988 Feb; 968(2):172-8. PubMed ID: 3257705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.